Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carrizumab plus thalidomide, pemetrexed and carboplatin for first-line treatment of advanced non-squamous non-small cell lung cancer
ChiCTR2000038265Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Oct 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in non-small cell lung cancer (NSCLC), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoint: Progression-free survival. Started Oct 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2000038265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000038265.